Infliximab (Remicade) is a biologic DMARD that targets tumor necrosis factor-alpha (TNF-α), helping to reduce joint inflammation and prevent long-term damage in rheumatoid arthritis. Unlike adalimumab or etanercept, infliximab is given by intravenous infusion in a clinic or infusion center, typically at weeks 0, 2, and 6, then every 8 weeks. It is often used in moderate to severe RA and is most effective when combined with methotrexate, which reduces the risk of the body forming antibodies against the drug. Side effects include infusion reactions (fever, rash, shortness of breath), higher risk of infections (TB, hepatitis, fungal infections), and rarely heart failure or demyelinating disease. While very effective, its IV administration and monitoring needs can be less convenient compared to self-injectable TNF inhibitors.